S&P Futures
4,021.00 +19.75 (+0.49%) Dow Futures
32,578.00 +144.00 (+0.44%) Nasdaq Futures
12,942.50 +52.25 (+0.41%) Russell 2000 Futures
1,759.70 +12.00 (+0.69%) Crude Oil
69.30 +0.04 (+0.06%) Gold
1,976.60 -7.20 (-0.36%)
After hours:
Chart Events
Performance Outlook
| Previous Close | 18.47 |
| Open | 18.35 |
| Bid | 0.00 x 1300 |
| Ask | 0.00 x 1800 |
| Day's Range | 18.35 - 19.30 |
| 52 Week Range | 8.39 - 23.91 |
| Volume | |
| Avg. Volume | 55,053 |
| Market Cap | 153.482M |
| Beta (5Y Monthly) | 1.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.21 |
| Earnings Date | Nov 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 46.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ANVS
Related Research
- Annovis Bio, Inc.Daily – Vickers Top Buyers & Sellers for 10/14/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast yearArgus Research
- PR Newswire
ANNOVIS BIO ANNOUNCES TWO PRESENTATIONS AT THE AD/PD™ 2023 INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASES
Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the Company will be making two presentations at the upcoming AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Disease, which is taking place from March 28 through April 1, 2023, in Gothenburg, Sweden.
- Zacks
COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar
COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.
- Zacks
Deciphera (DCPH) Gets Breakthrough Tag for Qinlock Expanded Use
The FDA grants breakthrough tag to Qinlock for treating second-line GIST patients with mutations in KIT Exon 11 and 17/18. Stock up on Tuesday in response.
